Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

Hallym University Medical Center150 enrolled

Overview

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

150

Conditions

Attention Deficit Disorder With Hyperactivity Methylphenidate Pharmacogenetics

Interventions

norepinephrine transporter polymorphism,GENETIC

OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ADHD * Physically healthy Exclusion Criteria: * Neurological illness * Concurrent additional psychiatric treatment * \< IQ 70 * Psychotic disorder * Major mood disorder needed other psychiatric medication * Significant suicidal ideation * Pervasive developmental disorder

Locations (1)

Hallym University Sacred Heart Hospital

Anyang-si, Gyeonggi-do, South Korea

Outcomes

Primary Outcomes

Korean ADHD Rating scale-parent version (KARS)

Time frame: baseline,1,2,4,8 weeks

Secondary Outcomes

Barkely side effect rating scale

Time frame: 1,2,4,8weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.